CDK4/6 inhibitor
Showing 1 - 25 of >10,000
Advanced Breast Cancer Trial in Lebanon (Fulvestrant, Neratinib, Alpelisib)
Not yet recruiting
- Advanced Breast Cancer
- Fulvestrant
- +4 more
-
Lebanon, New HampshireDartmouth Hitchcock Medical Center
Jun 28, 2023
Advanced HR-positive and HER2-negative Breast Cancer; CDK4/6 Inhibitor Treatment Failed Trial in Hangzhou (dalpiciclib;
Recruiting
- Advanced HR-positive and HER2-negative Breast Cancer; CDK4/6 Inhibitor Treatment Failed
- dalpiciclib; fluvestrant; compound gossypol acetate tablets
-
Hangzhou, Zhejiang, ChinazhejiangCH
Nov 9, 2023
Estrogen-receptor-positive Breast Cancer, HER2/Neu-Negative Breast Cancer, Advanced Breast Cancerv Trial in Chicago
Not yet recruiting
- Estrogen-receptor-positive Breast Cancer
- +3 more
- elacestrant, palbociclib, abemaciclib, ribociclib
-
Chicago, IllinoisNorthwestern University
Sep 25, 2023
Advanced HR+ HER2 Negative Breast Carcinoma Trial ((CDK)4/6 inhibitor)
Not yet recruiting
- Advanced HR+ HER2 Negative Breast Carcinoma
- (CDK)4/6 inhibitor
- (no location specified)
Sep 27, 2022
Breast Cancer Metastatic Cancer Trial in Shanghai (Fluzoparib, Dalpiciclib, Fulvestrant/AI)
Recruiting
- Breast Cancer Metastatic Cancer
- Fluzoparib
- +2 more
-
Shanghai, Shanghai, ChinaBreast cancer institute of Fudan University Cancer Hospital
Feb 26, 2023
Breast Cancer Trial in Baltimore (Endocrine Therapy and a CDK 4/6 inhibitor)
Recruiting
- Breast Cancer
- Endocrine Therapy and a CDK 4/6 inhibitor
-
Baltimore, MarylandJohns Hopkins University
Jul 18, 2022
Breast Cancer Metastatic Cancer Trial in Shanghai (Apatinib, Dalpiciclib, Fulvestrant/AI)
Recruiting
- Breast Cancer Metastatic Cancer
- Apatinib
- +2 more
-
Shanghai, Shanghai, ChinaBreast cancer institute of Fudan University Cancer Hospital
Feb 26, 2023
Advanced Breast Cancer Trial in Beijing (The combination of Dalpiciclib with physician-selected endocrine therapy, Chemotherapy
Recruiting
- Advanced Breast Cancer
- The combination of Dalpiciclib with physician-selected endocrine therapy
- Chemotherapy selected by the physician
-
Beijing, Beijing, ChinaPeking Union Medical College Hospital
May 22, 2023
CDK4/6 Inhibitors in Hormone Receptor-positive Advanced Breast
Not yet recruiting
- Breast Cancer
- CDK4/6 inhibitor
-
Shanghai, Shanghai, ChinaRenji Hospital, School of Medicine, Shanghai Jiao Tong Universit
Apr 5, 2023
Neurofibromatosis 1 Trial run by the National Cancer Institute (NCI) (Abemaciclib)
Recruiting
- Neurofibromatosis 1
-
Bethesda, MarylandNational Institutes of Health Clinical Center
Jan 20, 2023
HR+/HER2- Advanced Breast Cancer Trial in Beijing (Dalpiciclib, Chidamide)
Not yet recruiting
- HR+/HER2- Advanced Breast Cancer
-
Beijing, Beijing, ChinaThe Fifth Medical Center of PLA General Hospital
Oct 17, 2022
Estrogen Receptor-Positive, HER2-Negative Advanced Breast Cancer Trial (Giredestrant, Fulvestrant, Abemaciclib)
Not yet recruiting
- Estrogen Receptor-Positive, HER2-Negative Advanced Breast Cancer
- Giredestrant
- +6 more
- (no location specified)
Sep 26, 2023
Liposarcoma, Dedifferentiated Trial in New York (SPH4336)
Not yet recruiting
- Liposarcoma, Dedifferentiated
-
New York, New YorkColumbia University Medical Center
Oct 13, 2022
Locally Advanced Breast Cancer, Hormone Receptor Positive,HER2-negative Breast Cancer Trial in Jinan (letrozole)
Recruiting
- Locally Advanced Breast Cancer
- Hormone Receptor Positiveļ¼HER2-negative Breast Cancer
-
Jinan, Shandong, ChinaBreast Cancer Center, Shandong Cancer Hospital and Institute
Apr 11, 2023
Advanced Breast Cancer Trial in Seoul (Olaparib, Fulvestrant)
Not yet recruiting
- Advanced Breast Cancer
-
Seoul, Korea, Republic ofSeoul National University Hospital
Sep 12, 2022
Nasopharyngeal Carcinoma Trial in Guangzhou (Dalpiciclib Isetionate Tablets, Camrelizumab)
Recruiting
- Nasopharyngeal Carcinoma
- Dalpiciclib Isetionate Tablets, Camrelizumab
-
Guangzhou, Guangdong, ChinaDepartment of Nasopharyngeal Carcinoma, Sun Yat-sen University C
Feb 2, 2023
Metastatic Breast Cancer, Advanced Breast Cancer, HR-positive Breast Cancer Trial (OP-1250, Ribociclib, Alpelisib)
Not yet recruiting
- Metastatic Breast Cancer
- +3 more
- OP-1250
- +2 more
- (no location specified)
Aug 18, 2022
Breast Cancer, Advanced Breast Cancer Trial in Shanghai (Everolimus 10 mg, CDK4/6 Inhibitor SHR6390, Aromatase inhibitor and
Not yet recruiting
- Breast Cancer
- Advanced Breast Cancer
- Everolimus 10 mg
- +2 more
-
Shanghai, Shanghai, ChinaFudan University Shanghai Cancer Center
Jul 14, 2023
Lung Cancer Squamous Cell, Solid Tumors, Head & Neck Cancer Trial in Boston (Palbociclib, Gedatolisib)
Recruiting
- Lung Cancer Squamous Cell
- +3 more
-
Boston, Massachusetts
- +2 more
Jan 9, 2023